CAR-T therapies have proven effective. A few years ago they began as a rescue resource for those malignant blood tumors against which there was nothing to get rid of.
They manage to gain time to advance one of the most malignant brain tumors thanks to a new drugEGFR oncology. A special session has been dedicated on the last day of the Congress of the American Society of Medical Oncology (ASCO) to the needs of advanced therapies. It is the first treatment in nearly three decades that significantly improves overall survival.